MFC Co., Ltd., established in 2008, is a manufacturer specializing in APIs and key intermediates that GMP from the Korean Ministry of Food and Drug Safety (KMFDS) and AFM from PMDA are approved. MFC is continuously developing under quality Management through thorough quality control and quality assurance system, and technology management that puts best efforts in continuous process management and new technology development. MFC’s direction and aim are the development of excellent new APIs and key intermediates, and CMO/CDMO business in accordance with customer requirements, and incrementally Modified Drugs (IMD) & New Chemical Entity (NCE) using specialized technologies to go forward as a global pharmaceutical company. Especially, MFC is specialized in Pitavastatin & Rosuvastatin for prescription of hyperlipidemia.